

Information about proposed Board members prior to the Annual General Meeting 2026

Peter Zonabend

Born 1980

Chairman of the Board since 2022, member of the Board since 2019

Chairman of the Audit Committee and member of the Remuneration Committee

Other assignments

CEO of Arwidsro, Board assignments within Arwidsro and member of the Board of Hoist Finance AB (publ).

Previous experience

CEO of Victoria Investments Holding Ltd, 2010-2017, Law Firm Fylgia, Law Firm Björn Rosengren. Board assignments within Hövding Sverige AB, HQ AB, TCER AB, CBD Solutions AB.

Education

LL.M from Stockholm University, EMLE from Université Paul Cézanne Aix-Marseille III, Bsc in Business and Economics from Stockholm University and DU EAED from Université Paul Cézanne Aix-Marseille III.

Independence

Independent in relation to the company and its executive management

Not independent in relation to major shareholders of the company

Holdings of shares or other financial instruments in the company (including holdings of related persons)

720,000 shares. Manages 79,917 shares by proxy.

Hege Hellström

Born 1965

Member of the Board since 2019

Member of the Audit Committee

Other assignments

Chief Commercial Officer of Advicienne and partner at Belnor BVBA, a consultancy and investment company. Board member of Camurus AB, Guard Therapeutics AB and InflaRx GmbH.

Previous experience

Hege Hellström has over 30 years of experience in sales, marketing, strategic development and business management within the pharmaceutical industry, with particular experience in kidney medicine. Hege worked at the biotechnology company Sobi from 2013 until 2018 and was president for EMENAR (Europe, Middle East, North Africa and Russia). Prior to that, she was globally responsible for the Cardiovascular business area within Sanofi, VP Renal Europe and Head of Regional Liaisons at Sanofi, VP Renal and Endocrine Europe and General Manager Benelux at Genzyme. Before Genzyme, she was at Baxter for 13 years.

Education

B.Sc., Medical Laboratory Scientist, 1985, Oslo Metropolitan University, Norway.

Independence

Independent in relation to the company and its executive management
Independent in relation to major shareholders of the company

Holdings of shares or other financial instruments in the company (including holdings of related persons)

-

Pål Ryfors

Born 1983

Board member since 2022

Chairman of the Remuneration Committee and member of the Audit Committee

Other assignments

Chief Executive Officer of Aros Kapital AB.

Previous experience

Previously CEO and CFO of Episurf Medical, CFO of Marginalen Bank and Head of Group Controlling at Hoist Finance AB (publ). Prior to that, he was an investment banker at Societe Generale in London, a position he assumed after holding several leading positions in the restructuring of the Swedish operations of Kaupthing Bank.

Education

Bachelor in Financial Economics from Gothenburg School of Economics.

Independence

Independent in relation to the company and its executive management
Independent in relation to major shareholders of the company

Holdings of shares or other financial instruments in the company (including holdings of related persons)

-

Roger Tell

Born 1965

Board member since 2022

Member of the Remuneration Committee

Other assignments

Chief Medical Officer of Isofol Medical AB.

Previous experience

Vice President of Clinical Development at Aprea Therapeutics and International Clinical Project Director at Servier in Suresnes, France. He has an extensive experience as an oncologist as well as an advisor to biopharma companies, including Eli Lilly, Astra Zeneca and Merck Serono. Roger has

previously been the Chief Scientific Officer as well as acting Chief Executive Officer of Isofol Medical AB.

Education

Medical degree and a doctorate in experimental oncology from the Karolinska Institute in Sweden.

Independence

Independent in relation to the company and its executive management

Independent in relation to major shareholders of the company

Holdings of shares or other financial instruments in the company (including holdings of related persons)

-

Notes

The information above refers to the situation at the time of the notice of the Annual General Meeting.